• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布鲁顿酪氨酸激酶(BTK)的pleckstrin同源(PH)结构域中的点突变导致其激活。

Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.

作者信息

Li T, Tsukada S, Satterthwaite A, Havlik M H, Park H, Takatsu K, Witte O N

机构信息

Molecular Biology Institute, University of California, Los Angeles 90095, USA.

出版信息

Immunity. 1995 May;2(5):451-60. doi: 10.1016/1074-7613(95)90026-8.

DOI:10.1016/1074-7613(95)90026-8
PMID:7538439
Abstract

Bruton's tyrosine kinase (BTK) is a nonreceptor tyrosine kinase critical for B cell development and function. Mutations in BTK result in X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (xid) in mice. Using a random mutagenesis scheme, we isolated a gain-of-function mutant called BTK* whose expression drives growth of NIH 3T3 cells in soft agar. BTK* results from a single point mutation in the pleckstrin homology (PH) domain, where a Glu is replaced by Lys at residue 41. BTK* shows an increase in phosphorylation on tyrosine residues and an increase in membrane targeting. Transforming activity requires kinase activity, a putative autophosphorylation site, and a functional PH domain. Mutation of the SH2 or SH3 domains did not affect the activity of BTK*. Expression of BTK* could also relieve IL-5 dependence of a B lineage cell line. These results show that transformation activation and regulation of BTK are critically dependent on the PH domain.

摘要

布鲁顿酪氨酸激酶(BTK)是一种对B细胞发育和功能至关重要的非受体酪氨酸激酶。BTK突变会导致人类的X连锁无丙种球蛋白血症(XLA)和小鼠的X连锁免疫缺陷(xid)。我们采用随机诱变方案,分离出了一个名为BTK的功能获得性突变体,其表达可驱动NIH 3T3细胞在软琼脂中生长。BTK是由pleckstrin同源(PH)结构域中的一个单点突变导致的,在第41位残基处,一个谷氨酸被赖氨酸取代。BTK显示酪氨酸残基磷酸化增加以及膜靶向性增强。转化活性需要激酶活性、一个假定的自磷酸化位点和一个功能性PH结构域。SH2或SH3结构域的突变不影响BTK的活性。BTK*的表达还可缓解一个B系细胞系对IL-5的依赖性。这些结果表明,BTK的转化激活和调控严重依赖于PH结构域。

相似文献

1
Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain.布鲁顿酪氨酸激酶(BTK)的pleckstrin同源(PH)结构域中的点突变导致其激活。
Immunity. 1995 May;2(5):451-60. doi: 10.1016/1074-7613(95)90026-8.
2
Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).布鲁顿酪氨酸激酶的Src同源结构域3内的缺失导致X连锁无丙种球蛋白血症(XLA)。
J Exp Med. 1994 Aug 1;180(2):461-70. doi: 10.1084/jem.180.2.461.
3
Regulation of Btk function by a major autophosphorylation site within the SH3 domain.SH3结构域内一个主要自磷酸化位点对Btk功能的调节。
Immunity. 1996 May;4(5):515-25. doi: 10.1016/s1074-7613(00)80417-3.
4
Bruton's tyrosine kinase is essential for hydrogen peroxide-induced calcium signaling.布鲁顿酪氨酸激酶对于过氧化氢诱导的钙信号传导至关重要。
Biochemistry. 2001 Jul 10;40(27):8085-91. doi: 10.1021/bi0100788.
5
Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity.布鲁顿酪氨酸激酶的普列克底物蛋白同源结构域突变导致免疫缺陷,损害了肌醇1,3,4,5-四磷酸结合能力。
J Biol Chem. 1996 Nov 29;271(48):30303-6. doi: 10.1074/jbc.271.48.30303.
6
Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.通过替代受体激活布鲁顿酪氨酸激酶过程中两个调节性酪氨酸残基的磷酸化
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11526-33. doi: 10.1073/pnas.94.21.11526.
7
Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells.在单个活细胞中观察到布鲁顿酪氨酸激酶普列克底物蛋白同源结构域的磷脂酰肌醇3激酶依赖性膜结合。
J Biol Chem. 1999 Apr 16;274(16):10983-9. doi: 10.1074/jbc.274.16.10983.
8
Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases.磷脂酰肌醇3激酶γ与Src家族激酶协同激活布鲁顿酪氨酸激酶。
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13820-5. doi: 10.1073/pnas.94.25.13820.
9
An SH3-binding site conserved in Bruton's tyrosine kinase and related tyrosine kinases mediates specific protein interactions in vitro and in vivo.在布鲁顿酪氨酸激酶及相关酪氨酸激酶中保守的一个SH3结合位点在体外和体内介导特异性蛋白质相互作用。
J Biol Chem. 1995 Sep 1;270(35):20832-40. doi: 10.1074/jbc.270.35.20832.
10
Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.X连锁无丙种球蛋白血症中布鲁顿酪氨酸激酶基因的突变分析:鉴定出一个与免疫缺陷xid小鼠中发生改变的密码子相同的突变。
Hum Mol Genet. 1994 Jan;3(1):161-6. doi: 10.1093/hmg/3.1.161.

引用本文的文献

1
Conditional requirement for dimerization of the membrane-binding module for BTK signaling in lymphocyte cell lines.淋巴细胞系中BTK信号传导的膜结合模块二聚化的条件性要求。
Sci Signal. 2025 Jan 14;18(869):eado1252. doi: 10.1126/scisignal.ado1252.
2
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.在接受阿卡替尼或伊布替尼治疗的慢性淋巴细胞白血病进展的患者中,突变特征。
Blood. 2024 Sep 5;144(10):1061-1068. doi: 10.1182/blood.2023023659.
3
Phosphoinositides and intracellular calcium signaling: novel insights into phosphoinositides and calcium coupling as negative regulators of cellular signaling.
磷脂酰肌醇和细胞内钙离子信号转导:磷脂酰肌醇与钙离子偶联作为细胞信号转导负调节剂的新见解。
Exp Mol Med. 2023 Aug;55(8):1702-1712. doi: 10.1038/s12276-023-01067-0. Epub 2023 Aug 1.
4
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.边缘区淋巴瘤中新代 BTK 抑制剂泽布替尼应答的分子相关性。
Blood Adv. 2023 Jul 25;7(14):3531-3539. doi: 10.1182/bloodadvances.2022009412.
5
Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.口服生物可利用的 BTK PROTAC 在人源淋巴瘤 CDX 小鼠模型中对野生型和 C481 突变型 BTK 均具有活性。
Blood Adv. 2023 Jan 10;7(1):92-105. doi: 10.1182/bloodadvances.2022008121.
6
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.共价和非共价 BTK 抑制剂的结构-功能关系。
Front Immunol. 2021 Jul 19;12:694853. doi: 10.3389/fimmu.2021.694853. eCollection 2021.
7
Gene Therapies for Primary Immune Deficiencies.原发性免疫缺陷的基因疗法
Front Immunol. 2021 Feb 25;12:648951. doi: 10.3389/fimmu.2021.648951. eCollection 2021.
8
Development of a Model for Chemical Screening Based on Collateral Sensitivity to Target BTK C481S Mutant.
Cancers (Basel). 2020 Apr 7;12(4):901. doi: 10.3390/cancers12040901.
9
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.非共价抑制剂揭示 BTK 的看门人和自动抑制残基,这些残基控制其转化活性。
JCI Insight. 2019 Jun 20;4(12). doi: 10.1172/jci.insight.127566.
10
Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.细胞膜上布鲁顿酪氨酸激酶激活的结构机制。
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9390-9399. doi: 10.1073/pnas.1819301116. Epub 2019 Apr 24.